155 related articles for article (PubMed ID: 34474917)
21. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
22. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
Kankava K; Maisonneuve P; Mangogna A; Centonze G; Cattaneo L; Prinzi N; Pusceddu S; Fazio N; Pisa E; Di Domenico S; Bertani E; Mazzaferro V; Albertelli M; Grillo F; Milione M
J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808
[TBL] [Abstract][Full Text] [Related]
23. [Clinicopathological characterization of gastro-entero- pancreatic neuroendocrine tumors].
Borka K
Magy Onkol; 2018 Jul; 62(2):90-97. PubMed ID: 30027936
[TBL] [Abstract][Full Text] [Related]
24. Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.
Ooki A; Osumi H; Fukuda K; Yamaguchi K
Cancer Metastasis Rev; 2023 Sep; 42(3):1021-1054. PubMed ID: 37422534
[TBL] [Abstract][Full Text] [Related]
25. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S
Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732
[TBL] [Abstract][Full Text] [Related]
26. Indications for genetic study in gastro-entero-pancreatic and thoracic neuroendocrine tumors.
Araujo-Castro M
Endocrinol Diabetes Nutr (Engl Ed); 2023 Mar; 70 Suppl 1():63-73. PubMed ID: 36396595
[TBL] [Abstract][Full Text] [Related]
27. Current status of Interventional Radiology in the management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs).
Orgera G; Krokidis M; Cappucci M; Gourtsoyianni S; Tipaldi MA; Hatzidakis A; Rebonato A; Rossi M
Cardiovasc Intervent Radiol; 2015 Feb; 38(1):13-24. PubMed ID: 25366087
[TBL] [Abstract][Full Text] [Related]
28. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
29. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
30. Management of gastro-entero-pancreatic neuroendocrine tumours (GEP NET): an introduction.
Van Hootegem P; Borbath I; Verslype C
Acta Gastroenterol Belg; 2009; 72(1):27-8. PubMed ID: 19402367
[No Abstract] [Full Text] [Related]
31. Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias.
Albers MB; Almquist M; Bergenfelz A; Nordenström E
Langenbecks Arch Surg; 2020 Mar; 405(2):137-143. PubMed ID: 32291468
[TBL] [Abstract][Full Text] [Related]
32. Surgery for GEP-NETs.
Knigge U; Hansen CP
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):819-31. PubMed ID: 23582921
[TBL] [Abstract][Full Text] [Related]
33. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
[TBL] [Abstract][Full Text] [Related]
34. A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors.
Pelosi G; Bianchi F; Dama E; Metovic J; Barella M; Sonzogni A; Albini A; Papotti M; Gong Y; Vijayvergia N
Endocr Pathol; 2021 Sep; 32(3):396-407. PubMed ID: 33433886
[TBL] [Abstract][Full Text] [Related]
35. What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?
Stiefel R; Lehmann K; Winder T; Siebenhüner AR
BMC Cancer; 2023 Feb; 23(1):148. PubMed ID: 36782152
[TBL] [Abstract][Full Text] [Related]
36. Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression.
Pereira SS; Pereira R; Santos AP; Costa MM; Morais T; Sampaio P; Machado B; Afonso LP; Henrique R; Monteiro MP
Pathology; 2019 Oct; 51(6):593-599. PubMed ID: 31466863
[TBL] [Abstract][Full Text] [Related]
37. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.
Peracchi M; Conte D; Gebbia C; Penati C; Pizzinelli S; Arosio M; Corbetta S; Spada A
Eur J Endocrinol; 2003 Jan; 148(1):39-43. PubMed ID: 12534356
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of small-cell versus large-cell gastroenteropancreatic neuroendocrine carcinomas: A population-based study.
Abdel-Rahman O; Fazio N
J Neuroendocrinol; 2021 May; 33(5):e12971. PubMed ID: 33870570
[TBL] [Abstract][Full Text] [Related]
39. Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach.
Rozenblum L; Mokrane FZ; Yeh R; Sinigaglia M; Besson FL; Seban RD; Zadro C; Dierickx L; Chougnet CN; Partouche E; Revel-Mouroz P; Zhao B; Otal P; Schwartz LH; Dercle L
Eur J Radiol; 2020 Jan; 122():108743. PubMed ID: 31783345
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients.
Huang YC; Yang NN; Chen HC; Huang YL; Yan WT; Yang RX; Li N; Zhang S; Yang PP; Feng ZZ
World J Gastroenterol; 2021 Feb; 27(7):624-640. PubMed ID: 33642833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]